Ulcerative Colitis Pill Hits Record Remission Rates But Cancer Cases Emerge
Obefazimod hit 51% remission in UC patients — the highest placebo-adjusted rate ever — but cancer signals are raising safety red flags.
Summary
A new daily pill for ulcerative colitis called obefazimod showed the strongest long-term remission rates ever recorded in a clinical trial for the condition. In a Phase 3 study of 580 patients, roughly 51% of those on either dose achieved clinical remission over 44 weeks, compared to just 10.4% on placebo. That placebo-adjusted gap is unprecedented for a long-term UC trial. However, the promising results were overshadowed by reports of cancer cases among treated patients, sending the drug company's stock sharply lower. Ulcerative colitis is a chronic inflammatory bowel disease that significantly impacts quality of life and is associated with elevated colorectal cancer risk. Whether obefazimod itself contributed to cancer risk or whether cases reflect the underlying disease burden remains a critical open question.
Detailed Summary
Ulcerative colitis is a chronic autoimmune condition causing persistent gut inflammation, and it remains difficult to treat effectively over the long term. Many patients cycle through biologics and other therapies without achieving lasting remission, making this trial a closely watched moment in inflammatory bowel disease research.
Abivax's Phase 3 maintenance trial enrolled 580 patients who had already responded to earlier, shorter trials of obefazimod — a once-daily oral pill. After 44 weeks, approximately 51% of patients on either the 25mg or 50mg dose were in clinical remission. This compares starkly to just 10.4% on placebo, giving obefazimod the highest placebo-adjusted remission rate ever reported in a long-term ulcerative colitis trial, according to analyst Thomas Smith of Leerink.
The magnitude of the efficacy signal is significant. Current standard-of-care biologics and JAK inhibitors typically achieve placebo-adjusted remission rates well below 40% in comparable trials. An oral pill that outperforms injectable biologics in remission rates would represent a meaningful shift in treatment options for the estimated 1–2 million Americans living with UC.
However, the trial also revealed cancer cases among treated patients, a safety signal serious enough to collapse the company's stock in after-hours trading. The specific number, cancer types, and whether causality can be established remain unclear from the available reporting. Chronic UC itself elevates colorectal cancer risk, complicating attribution. Regulators will scrutinize whether the cancer incidence exceeds background rates expected in this population.
For health-conscious adults, the practical takeaway is that gut inflammation management remains a critical longevity lever — chronic colitis accelerates systemic inflammatory burden. This drug may eventually offer a superior oral option, but its safety profile requires full regulatory review before any conclusions can be drawn about clinical use.
Key Findings
- 51% of obefazimod-treated patients achieved clinical remission vs. 10.4% on placebo over 44 weeks.
- Placebo-adjusted remission rate is the highest ever reported in a long-term ulcerative colitis trial.
- Obefazimod is an oral daily pill, potentially more convenient than current injectable biologics.
- Cancer cases were detected among treated patients, triggering major investor concern and stock decline.
- Causality between the drug and cancer is unconfirmed — UC itself raises baseline cancer risk.
Methodology
This is a news report from STAT News, a credible specialist health and biotech publication. The article summarizes Phase 3 trial results announced by Abivax; the full trial data have not yet been peer-reviewed or published in a journal based on this report. Analyst commentary from Leerink's Thomas Smith is cited to contextualize efficacy benchmarks.
Study Limitations
The article is paywalled after the summary, so full safety data — including cancer types, incidence rates, and patient context — are not available for review. Causality between obefazimod and cancer cannot be assessed without complete trial data. Readers should consult the primary trial publication and FDA review documents when available before drawing conclusions.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.